Carl L. Gordon - 23 Jul 2026 Form 4 Insider Report for Scribe Therapeutics, Inc. (SCTX)

Reporting relationship: Director
Issuer ticker: SCTX
Reported as of: 23 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 29 Jul 2026, 18:50:42 UTC
Prior SEC filing: 05 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Carl L. Gordon

Key filing fact

Carl L. Gordon filed Form 4 for Scribe Therapeutics, Inc. (SCTX) on 29 Jul 2026.

Key facts

This page summarizes Carl L. Gordon's Form 4 filing for Scribe Therapeutics, Inc. (SCTX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 29 Jul 2026, 18:50.

Change

Previous filing in this sequence was filed on 05 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001282930 Primary reporting owner

GORDON CARL L

Relationship: Director
Address: C/O SCRIBE THERAPEUTICS INC., 1150 MARINA VILLAGE PKWY, ALAMEDA
Signature: /s/ Carl L. Gordon
Signature date: 29 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SCTX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +348,825
Change %
Price
Shares after: 348,825
Date: 27 Jul 2026
Ownership: See footnotes
Footnotes: F1, F3, F4

SCTX transaction

Common Stock

Purchase

Transaction value
Shares: +1,000,000
Change %: +287%
Price: $15.00^*
Shares after: 1,348,825
Date: 27 Jul 2026
Ownership: See footnotes
Footnotes: F2, F3, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SCTX transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value
Shares: -2,065,672
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 27 Jul 2026
Ownership: See footnotes
Underlying class: Common Stock
Underlying amount: 348,825
Exercise price
Footnotes: F1, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.1689 basis upon the closing of the Issuer's initial public offering on July 27, 2026 without payment of consideration. The Series B Preferred Stock has no expiration date.

Footnote F2

Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.

Footnote F3

The shares are held directly by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.

Footnote F4

Each of the Reporting Person, OrbiMed Advisors and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.